Daniel Shoemaker Ph.D. — Chief Scientific Officer at Fate Therapeutics

Dr. Daniel D. Shoemaker, also known as Dan, Ph.D. has been the Chief Scientific Officer of Fate Therapeutics, Inc. since May 2015. Dr. Shoemaker served as Chief Research Officer of Fate Therapeutics, Inc. since January 1, 2015 until May 2015. Dr. Shoemaker served as the Chief Technology Officer at Fate Therapeutics, Inc. since February 2009 until January 2015. Dr. Shoemaker has over 15 years of experience to the design, development and implementation of quantitative cell state detection technologies. His primary responsibilities are include advancing Fate Therapeutics iPS cell technology platform to create and differentiate virus-free iPS cells. He served as Chief Scientist of ICx Biosystems, where he was responsible for the design and development of molecular tools to enrich and analyze rare cell populations. From 2003 to 2005, he served as Chief Scientific Officer of GHC Technologies, where he led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics. From 1998 to 2003, Dr. Shoemaker held several positions at Merck Research Laboratories, including Director of Target Discovery, senior director at Rosetta Inpharmatics and research fellow in the Department of Molecular Neurosciences. Throughout his career, his research has achieved publication in top journals, including Nature, Science and Nature Biotechnology. Dr. Shoemaker joined Rosetta Inpharmatics in 1998 where he initially led an R&D group to develop novel applications of its proprietary ink-jet microarray technology. He went on to lead a Genomic Discovery group at Rosetta that mined the draft human GHC Technologies Inc. genome for novel drug targets and developed methods for monitoring alternative splicing on a genome-wide scale. Dr. Shoemaker's expertise in integrating technology, informatics and biology has allowed him to develop innovative approaches for addressing large-scale biological questions. Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from University of California, Santa Barbara.